ArticlePharmaceutical research2026
Development of a Water-soluble Form of Umifenovir Through the Synergistic Action of a Surfactant and a Hydrotropic Agent: A Multifactorial Study.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThe aim of this study was to develop a water-soluble form of umifenovir (UMF) through the synergistic action of the non-ionic surfactant Brij35 and choline bitartrate (ChB), and to investigate the solubility, aggregation and diffusion.
methodsUMF solubilization was assessed using the saturation shake-flask method. The hydrodynamic radii and aggregation behavior of Brij35 micelles were characterized by light scattering. UMF diffusion rate was investigated using a Franz diffusion cell and an artificial membrane.
resultIntroduction of ChB into the UMF/Brij35 system reduced the degree of association with Brij35 micelles and the micelle/water partition coefficient, increased the solubilizing capacity, and modulated the aggregation behavior of Brij35 and permeability. The increase in total (micelle-associated and freely dissolved) drug solubility of UMF in buffer рН 7.4 in the system with the minimal Brij35 concentration (0.45%) was 18.4%, whereas upon addition of ChB (1.0%) - 35.2%. However, calculation of the molecularly dissolved fractions (f
conclusionThis study highlights the advantage of simultaneously using low concentrations of Brij35 and ChB to achieve a synergistic action for maximal improvement in UMF solubility with a minimal reduction in permeability.
Indexed as
Identifiers
42086874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.